LivaNova (NasdaqGS:LIVN) Q4 2025 Earnings call February 25, 2026 08:00 AM ET Company ParticipantsAhmet Tezel - Chief Innovation OfficerAlex Shvartsburg - CFOAnthony Petrone - Managing Director and Equity ResearchBrianna Gotlin - Vice President of Investor RelationsJohn McAulay - Associate VPVladimir Makatsaria - CEOConference Call ParticipantsAdam Maeder - Managing Director and Senior Research AnalystBrett Fishman - VP and Senior Equity Research AnalystDavid Rescott - Senior Research AnalystMichael Polark - ...

2026年初，广州文石信息科技股份有限公司（以下简称"文石"）正式向香港联交所递交了上市申请。这个消息之所以值得关注，并非因其融资规模之巨， 而在于其背后所承载的产业象征意义——这是自2010年汉王科技以"墨水屏终端"概念登陆A股以来，时隔16年，第二家以此为核心业务谋求资本市场认可 的企业，阅读载体再度站上资本风口。 16年前，iPad刚刚问世，移动互联网浪潮席卷全球，以汉王为代表的电纸书企业曾被寄予厚望，被视为引领阅读革命的先锋。汉王科技上市不久，股价从 40多元飙升到90多元，后来一度达到巅峰的175元，阅读器一年销量上百万台。那时，北京一些枢纽地铁站的地下通道里，各大阅读器的广告铺天盖地。 然而，好景不长，多功能、高性能的平板电脑迅速将功能单一的电纸书挤入边缘地带，使其沦为网友口中自嘲的"泡面神器"，汉王科技的股价也很长一段 时间徘徊在10元左右，公司高管上市之初怒砸"苹果"的故事成为行业笑谈。Kindle进入中国市场之后，一度短暂带动了国内电纸书阅读风潮的复苏，但市 场并没有迎来再一次的爆发。专注数字阅读的掌阅科技也曾成立专门的硬件公司，后来为了不影响公司的财务报表，只好把这块业务排除在上市公司之 ...

Core Insights - Infineon released its "2026 GaN Technology Outlook," projecting a compound annual growth rate (CAGR) of 44% for the gallium nitride (GaN) market from 2025 to 2030 [1] - Revenue from GaN technology is expected to reach $920 million in 2026, representing a 58% year-over-year increase [1] - GaN power devices are rapidly entering emerging fields such as AI data centers, robotics, electric vehicles, renewable energy, digital health, and quantum computing, driving higher performance and energy-efficient system designs [1] - By 2026, GaN technology is anticipated to further penetrate the power electronics industry [1]

依照该公司说法，开发这一数字诊断平台旨在实现人们日常生活中的持续监测和预防性健康管理。 这一诊断平台在1月的美国拉斯维加斯消费电子展（CES）上获得创新奖。该公司表示，希望通过推广 基于可穿戴设备的数字健康与医疗人工智能融合模式，加速构建以预防为核心的医疗生态系统，"在医 院之外守护生命安全"。 （文章来源：新华社） 韩国一家数字医疗初创企业9日说，已开发出一款基于人工智能(AI)的数字诊断平台，可以帮助人们在 家尽早发现心脏病发作的先兆。 韩联社报道，这家公司开发的平台可实时整合智能手表等可穿戴设备生成心电图数据，帮助使用者在家 庭环境中侦测21种心律失常类型，通过分析心电图数据来评估未来24小时内心脏骤停的可能性，并向患 者、主治医师及急救中心即时发出警报。 ...

南方财经 21世纪经济报道记者袁思杰广州报道 "本次会议，我们期待向各成员经济体学习，了解如何借鉴运用已有的数字健康解决方案，探讨如何能 从中汲取最佳经验，实现共同繁荣发展。" 2月1日，马来西亚卫生部数字健康总监Mahesh Appanan在亚 太经合组织（APEC）第一次高官会前对记者表示，自己是首次来到中国，非常感谢中国作为本次会议 东道主的热情接待。 Mahesh Appanan指出，中国经济发展前景广阔，且在医疗健康以及数字健康领域引入了大量前沿技 术："我一直在思考如何能更充分地借鉴中国的经验，而亲身来到中国的这两天，已经让我获得了诸多 关于如何推动马来西亚医疗与数字健康转型的启发。" 2月1日至10日，广州举办APEC第一次高官会及相关会议。作为APEC"中国年"首场正式活动，本次会议 将聚焦2026年APEC会议主题"建设亚太共同体，促进共同繁荣"和三大优先领域"开放、创新、合作"， 全面启动各领域各机制合作，深入讨论具体合作，为11月领导人非正式会议积累成果。 据悉，会议期间将举办50多场活动，有约1000名来自APEC各成员经济体、秘书处、工商咨询理事会等 代表与会。 （文章来源：21世纪 ...

Core Insights - Ant Group is shifting its focus from financial services to health management, aiming to address both wealth and health concerns of the public, as articulated by CEO Han Xinyi [3][6] - The company is investing heavily in its health AI assistant "Afu," which aims to provide comprehensive health management services, indicating a strategic pivot towards the health sector [6][19] Group 1: Strategic Shift to Health - Ant Group's decision to enter the health sector is driven by a combination of technological advancements, societal needs, and its corporate DNA, marking a significant strategic choice for the next decade [2][3] - The health sector is seen as a vast market with long-tail demands that have not been effectively digitized, contrasting with previous internet healthcare models that focused narrowly on selling medications [8][10] Group 2: Market Dynamics and Demand - There is a strong policy push from the government to integrate AI into healthcare, with multiple initiatives aimed at enhancing health services through technology [10] - Health is identified as a fundamental need that persists through economic cycles, with increasing public anxiety about health management, particularly in the context of uneven healthcare resource distribution [10][12] Group 3: Technological Advancements - The rise of AI technology is expected to enhance traditional healthcare services, making them more efficient and personalized, which aligns with Ant Group's strategy to leverage its technological capabilities in a specialized field [12][19] - Over a thousand doctors have already created AI avatars on Afu, indicating a proactive approach to enhancing healthcare delivery and expanding service capacity [12] Group 4: Investment and Commitment - Ant Group is committing substantial financial resources to the health sector, with projected annual investments reaching "tens of billions" in 2024 and 2025, reflecting a serious commitment to succeed in this domain [15][16] - The company views its health initiative as a critical component of its identity in the AI era, aiming to replicate its successful financial service model in the healthcare space [16][18] Group 5: Future Vision and Ecosystem - Afu is designed to evolve into an open health data and service ecosystem, integrating with various health monitoring devices to provide continuous health management services [19] - The ultimate goal is to create a comprehensive health service platform that not only addresses immediate health concerns but also builds long-term user trust and engagement [18][19] Group 6: Competitive Landscape - The health sector is becoming increasingly competitive, with major tech companies like Amazon and Anthropic also entering the AI health space, indicating a broader industry trend towards digital health solutions [23][24] - Ant Group's strategic investments and innovations are positioned to capitalize on this trend, suggesting a well-defined roadmap for future growth in the health sector [24]

Investment Rating - The report does not explicitly provide an investment rating for the tuberculosis (TB) industry in the Asia-Pacific region. Core Insights - Tuberculosis remains a significant public health challenge, particularly in the Asia-Pacific region, which accounts for a substantial portion of the global TB burden. The report highlights that five countries—India, Indonesia, China, the Philippines, and Pakistan—contribute to 56% of global TB cases [5][49]. - There is an urgent need for new drug therapies to address the rising rates of drug-resistant TB, particularly multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains [50][53]. - The report emphasizes the importance of tailored approaches in clinical trial designs to address the diverse challenges faced in different countries within the Asia-Pacific region [51][52]. Summary by Sections 1. Overview of Tuberculosis in the Asia-Pacific Region - TB is a leading cause of infectious disease-related deaths globally, with the highest incidence in Southeast Asia, followed by Africa and the Western Pacific [5]. - The burden of TB is particularly severe in the Asia-Pacific region, with significant economic impacts on affected families [5]. 2. Global TB Management Standards - The World Health Organization (WHO) recommends a standardized 6-month treatment regimen for drug-sensitive TB (DS-TB) and has introduced a new 4-month regimen for drug-resistant TB [10][11]. 3. Challenges and Potential Solutions in TB Clinical Trials - The report identifies various challenges in conducting TB clinical trials, including patient adherence, economic barriers, and stigma associated with the disease [19][25][30]. - It suggests that community engagement and education are crucial for improving patient recruitment and retention in clinical trials [22][30]. 4. TB Clinical Trial Landscape - The Asia-Pacific region is highlighted as a growth center for clinical trials, with a large patient population and increasing logistical support for trial operations [47][48]. 5. Opportunities in TB Clinical Trials - The report notes the potential for clinical trials to address unmet needs in TB diagnostics, treatment, and vaccine development, particularly in high-burden countries [49][50]. 6. Key Recommendations - The report recommends recognizing the diversity of countries in the Asia-Pacific region and adopting customized approaches to enhance the effectiveness of clinical trials [52]. - It emphasizes the need for ongoing support and monitoring to ensure patient adherence and successful trial outcomes [39][54].

2026年世界经济论坛年会(冬季达沃斯论坛)上，诺华公司董事会主席Giovanni Caforio博士宣布一项重要合作：诺华基金会、文莱卫生部、医渡科技(02158)旗 下EVYD公司将联合实施数智驱动的心血管疾病防控项目——CARDIO4Cities。该项目依托由EVYD助力建设的文莱国家数字卫生平台BruHealth，旨在借助 数据与AI工具，实现高危人群的早期识别与精准干预，从而降低心血管疾病及其急性并发症的发生风险，提升文莱居民的心血管健康管理水平。 这一兼具公共卫生价值与创新意义的合作，已被世界经济论坛官网重点报道。 诺华公司董事会主席Giovanni Caforio博士致辞 在由诺华基金会、诺和诺德及世界心脏病联盟共同举办的"通过合作与人工智能扩大社会影响力创新"达沃斯论坛主题会议上，医渡科技创始人、董事长宫如 璟与飞利浦基金会董事会主席Marnix van Ginneken围绕数字健康与公共卫生体系创新展开对话，诺华基金会负责人Ann Aerts博士担任主持人。 宫如璟指出，公共卫生的高质量发展是一项系统工程，其关键在于技术创新与跨界协作能否形成持续放大的系统能力。她强调，此次在文莱启动的 CA ...

Core Insights - Novartis announced a significant collaboration at the 2026 World Economic Forum, focusing on a data-driven cardiovascular disease prevention project called CARDIO4Cities, in partnership with the Brunei Ministry of Health and EVYD, a subsidiary of Yidu Tech [1] - The project aims to leverage the BruHealth digital health platform to identify high-risk populations early and implement precise interventions, thereby reducing the risk of cardiovascular diseases and improving health management in Brunei [1] Group 1: Project Overview - The CARDIO4Cities project is designed to address the high burden of cardiovascular diseases, which are a leading cause of death globally, accounting for over 70% of deaths [8] - In Brunei, cardiovascular diseases are the primary cause of mortality, putting pressure on the public health system [8] - The project will utilize AI to categorize cardiovascular disease risk levels among the population and provide tailored management plans [8][9] Group 2: Technological and Systemic Innovations - The initiative represents a strategic national-level practice aimed at transforming public health systems from reactive to proactive, and from fragmented services to systematic governance [8] - The BruHealth platform, initially developed for tracking infectious diseases during the pandemic, has evolved into a comprehensive digital infrastructure covering over 85% of Brunei's population [10] - The collaboration will enhance data integration, analysis, and technical support for the project, with EVYD playing a key role [10] Group 3: Global Implications - The CARDIO4Cities project has been implemented in over 40 cities worldwide, with previous implementations showing potential to increase blood pressure control rates by 3 to 6 times and reduce stroke incidence by up to 13% [10] - This collaboration not only provides a new solution for cardiovascular disease prevention in Brunei but also serves as a reference model for global non-communicable disease management [11] - The project is expected to significantly improve public health services in Brunei and reduce the health and social burden of cardiovascular diseases [11]

2026 年 1 月， Johnson & Johnson MedTech 宣布，在美国市场正式推出 Arbrea Breast Simulator Surgeon App for Mentor 。该产品是一款面向整形外科医生的 移动端数字化咨询工具 ，可运行于平板和智能手机， 用于乳房手术（尤其是隆乳手术）的术前沟通与方案展示。 从定位上看，该应用并非手术器械或术中系统，而是服务于 医患沟通与决策前端 的数字工具，目标在于提 升咨询阶段的可视化程度与沟通效率。 3. 实时辅助医生与患者讨论 医生可在咨询过程中动态展示不同方案的潜在效果，支持更结构化的方案对比与讨论，而非单向讲解。 从 技术属性上看，该产品属于 数字健康与三维可视化软件 ，并未涉及术中导航或治疗决策。 # 了解 A rbrea （ 一 ） 功能与技术特点拆解 根据强生 MedTech 的公开说明，Arbrea 应用的核心功能集中在以下几个方面： 1. 快速生成个性化 3D 模拟结果 应用可在约 60 秒内 生成患者个性化的三维模拟效果，用于展示不同隆乳方案可能带来的外观变化。 2. 替代传统"物理尺码 + 图片库"的沟通方式 强生指出，目前多 ...